Ying-Shan Han

2.5k total citations
58 papers, 2.0k citations indexed

About

Ying-Shan Han is a scholar working on Infectious Diseases, Virology and Molecular Biology. According to data from OpenAlex, Ying-Shan Han has authored 58 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Infectious Diseases, 31 papers in Virology and 28 papers in Molecular Biology. Recurrent topics in Ying-Shan Han's work include HIV Research and Treatment (31 papers), HIV/AIDS drug development and treatment (30 papers) and Biochemical and Molecular Research (13 papers). Ying-Shan Han is often cited by papers focused on HIV Research and Treatment (31 papers), HIV/AIDS drug development and treatment (30 papers) and Biochemical and Molecular Research (13 papers). Ying-Shan Han collaborates with scholars based in Canada, China and Netherlands. Ying-Shan Han's co-authors include Mark A. Wainberg, Thibault Mésplède, Stéphane Bastianetto, Rémi Quirion, Peter K. Quashie, Hongtao Xu, Maureen Oliveira, Jean‐Guy Chabot, Wenhua Zheng and Robert Verpoorte and has published in prestigious journals such as Journal of the American Chemical Society, PLoS ONE and Journal of Virology.

In The Last Decade

Ying-Shan Han

58 papers receiving 2.0k citations

Peers

Countries citing papers authored by Ying-Shan Han

Since Specialization

Citations

This map shows the geographic impact of Ying-Shan Han's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ying-Shan Han with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ying-Shan Han more than expected).

Fields of papers citing papers by Ying-Shan Han

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ying-Shan Han. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ying-Shan Han. The network helps show where Ying-Shan Han may publish in the future.

Co-authorship network of co-authors of Ying-Shan Han

This figure shows the co-authorship network connecting the top 25 collaborators of Ying-Shan Han. A scholar is included among the top collaborators of Ying-Shan Han based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ying-Shan Han. Ying-Shan Han is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Diverse Types of Diterpenoids with an Aromatized C Ring from the Twigs of Podocarpus imbricatus 2020 ·Journal of Natural Products ·Bin Zhou, Yuhao Ren, Ying-Shan Han, Thibault Mésplède, Jian‐Min Yue	13
2	Regulation of protein kinase Cδ Nuclear Import and Apoptosis by Mechanistic Target of Rapamycin Complex-1 2019 ·Scientific Reports ·(unknown), Alexander A. Goldberg, Ayesha Baig, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), T.M. Schmeing, Ying-Shan Han, Jeffrey Downey, Maziar Divangahi, Philippe P. Roux, Arnold S. Kristof	2
3	The S230R Integrase Substitution Associated With Virus Load Rebound During Dolutegravir Monotherapy Confers Low-Level Resistance to Integrase Strand-Transfer Inhibitors 2018 ·The Journal of Infectious Diseases ·Hanh Thi Pham, (unknown), (unknown), Said Hassounah, (unknown), (unknown), (unknown), Ying-Shan Han, (unknown), Marc van der Valk, Bluma Brenner, Charles A. Boucher, Bart Rijnders, Jeroen J. A. van Kampen, Thibault Mésplède, Mark A. Wainberg	28
4	Investigational drugs for the treatment of Zika virus infection: a preclinical and clinical update 2018 ·Expert Opinion on Investigational Drugs ·Ying-Shan Han, Thibault Mésplède	21
5	Differences among HIV-1 subtypes in drug resistance against integrase inhibitors 2016 ·Infection Genetics and Evolution ·Ying-Shan Han, Thibault Mésplède, Mark A. Wainberg	38
6	Purification of Zika virus RNA-dependent RNA polymerase and its use to identify small-molecule Zika inhibitors 2016 ·Journal of Antimicrobial Chemotherapy ·Hongtao Xu, Said Hassounah, Susan P. Colby-Germinario, Maureen Oliveira, Clare Fogarty, Yudong Quan, Ying-Shan Han, (unknown), (unknown), Bluma Brenner, Brent R. Stranix, Mark A. Wainberg	59
7	Will drug resistance against dolutegravir in initial therapy ever occur? 2015 ·Frontiers in Pharmacology ·Mark A. Wainberg, Ying-Shan Han	29
8	Differential Effects of the G118R, H51Y, and E138K Resistance Substitutions in Different Subtypes of HIV Integrase 2015 ·Journal of Virology ·Peter K. Quashie, (unknown), (unknown), Nathan Osman, Ying-Shan Han, Said Hassounah, Yolanda Lie, Wei Huang, Thibault Mésplède, Mark A. Wainberg	64
9	Structural Studies of the HIV-1 Integrase Protein: Compound Screening and Characterization of a DNA-Binding Inhibitor 2015 ·PLoS ONE ·Peter K. Quashie, Ying-Shan Han, Said Hassounah, Thibault Mésplède, Mark A. Wainberg	16
10	The R263K substitution in HIV-1 subtype C is more deleterious for integrase enzymatic function and viral replication than in subtype B 2015 ·AIDS ·Thibault Mésplède, Peter K. Quashie, Said Hassounah, Nathan Osman, Ying-Shan Han, (unknown), Diane N. Singhroy, Mark A. Wainberg	15
11	The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness 2014 ·Retrovirology ·(unknown), Thibault Mésplède, Peter K. Quashie, Nathan Osman, Ying-Shan Han, Mark A. Wainberg	69
12	Identification of an env-defective HIV-1 mutant capable of spontaneous reversion to a wild-type phenotype in certain T-cell lines 2014 ·Virology Journal ·Yudong Quan, Hongtao Xu, Victor G. Kramer, Ying-Shan Han, Richard D. Sloan, Mark A. Wainberg	4
13	Anti-HIV Securinega alkaloid oligomers from Flueggea virosa 2014 ·Tetrahedron ·Hua Zhang, Ying-Shan Han, Mark A. Wainberg, Jian‐Min Yue	26
14	Development of a fluorescence-based HIV-1 integrase DNA binding assay for identification of novel HIV-1 integrase inhibitors 2013 ·Antiviral Research ·Ying-Shan Han, Wei‐Lie Xiao, Peter K. Quashie, Thibault Mésplède, Hongtao Xu, Eric Deprez, Olivier Delelis, Jian‐Xin Pu, Han‐Dong Sun, Mark A. Wainberg	15
15	Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure 2013 ·Retrovirology ·Thibault Mésplède, Peter K. Quashie, Nathan Osman, Ying-Shan Han, Diane N. Singhroy, Yolanda Lie, Christos J. Petropoulos, Wei Huang, Mark A. Wainberg	106
16	Comparative Neuroprotective Properties of Stilbene and Catechin Analogs: Action Via a Plasma Membrane Receptor Site? 2009 ·CNS Neuroscience & Therapeutics ·Stéphane Bastianetto, Yvan Dumont, Ying-Shan Han, Rémi Quirion	45
17	Specific Plasma Membrane Binding Sites for Polyphenols, Including Resveratrol, in the Rat Brain 2006 ·Journal of Pharmacology and Experimental Therapeutics ·Ying-Shan Han, Stéphane Bastianetto, Yvan Dumont, Rémi Quirion	73
18	Neuroprotective effects of resveratrol against β‐amyloid‐induced neurotoxicity in rat hippocampal neurons: involvement of protein kinase C 2004 ·British Journal of Pharmacology ·Ying-Shan Han, Wenhua Zheng, Stéphane Bastianetto, Jean‐Guy Chabot, Rémi Quirion	250
19	High-performance liquid chromatography assay for 1-deoxy-d-xylulose 5-phosphate synthase activity using fluorescence detection 2003 ·Journal of Chromatography A ·Ying-Shan Han, Cesare Sabbioni, Robert van der Heijden, Robert Verpoorte	7
20	Biosynthesis of anthraquinones in cell cultures of the Rubiaceae 2001 ·Plant Cell Tissue and Organ Culture (PCTOC) ·Ying-Shan Han, Robert van der Heijden, Robert Verpoorte	111

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact